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S U M M A R Y
The decision on the right empirical treatment in bacteremia places particular demands on the clinician.
As long as no microbiological diagnosis can be immediately drawn, the clinical diagnosis together with
knowledge of local antimicrobial resistance must determine the antimicrobial choice. The use of several
ampliﬁcation, hybridization, and mass spectrometry methods has been studied in patient cohorts in
comparison with blood culture-based conventional techniques. However, no clinical outcome trials have
been conducted in which the use of these novel methods would guide antimicrobial therapy. Local
differences in bacterial antimicrobial resistance cause differences in the regional need for molecular
methods for the early detection of resistance mechanisms. The implementation of novel methods in
clinical use requires active discussion between laboratory experts and clinicians. Providing rapid
susceptibility results using conventional methods can lead to timely changes to appropriate
antimicrobial therapy and the costs are lower than with the molecular methods. Gram-stain information
in combination with clinical data is an underestimated, underused, rapid, and economical means of
assessing the etiology of blood stream infection.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. What does the right decision on empirical antimicrobial
therapy in bacteremia require of the clinician?
Clinical diagnosis is the basis of antimicrobial choice. The
patient’s underlying diseases, immunosuppression, age, and
clinical specialty affect the decision on antimicrobial therapy
(Table 1). The distribution of causative agents varies between
healthcare- and hospital-acquired infections and between differ-
ent clinical specialties.1 Disease severity has an impact on the
antimicrobial choice. Local and global antimicrobial resistance has
an impact on choices and a history of international travel may
affect decisions. The emergence of resistant enterobacteria strains,
extended-spectrum beta-lactamase (ESBL)-producing bacteria,
and carbapenemase-producing strains has set further challenges.
One interesting study conducted by Byl and associates in the 1990s
highlighted the importance of clinical expertise in the choice of
antimicrobials. The study showed that empirical treatment was
appropriate in 63% of episodes and the proportion reached 78% for
episodes treated by infectious disease specialists, compared with
54% for others.2* Corresponding author. Tel.: +358 (0)50 5603081/+358 3 31165111.
E-mail address: Reetta.Huttunen@uta.ﬁ (R. Huttunen).
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http://dx.doi.org/10.1016/j.ijid.2013.04.0182. Bacteremia detection by blood cultures and information
obtained from Gram stain
The proportion of positive to negative blood cultures is known
to vary according to the setting. Established algorithms to direct
blood culture ordering have been challenged on this basis.3 One
recent study showed that leukocytosis or fever as isolated
parameters are poor indicators of bacteremia. The study in
question, gathering data on 35 studies, indicated that the pretest
probability varies between the different clinical conditions for
which physicians often obtain blood cultures and that the
probability of bacteremia in any series of consecutive patients is
low.3 Syndromes with low probability of bacteremia include
ambulatory patients, patients with cellulitis, and those with
community-acquired pneumonia and community-acquired fever.
The probability of bacteremia was intermediate in patients with
pyelonephritis and high in patients with severe sepsis, septic
shock, or acute bacterial meningitis. The authors concluded that
blood cultures should not be ordered for adult patients with
isolated fever or leukocytosis without ﬁrst considering the pretest
probability, and that systemic inﬂammatory response syndrome
criteria (SIRS) and the decision rule based on the probability of
bacteremia may be helpful in identifying patients who do not need
blood cultures.3 However, in many hospitals, blood cultures areses. Published by Elsevier Ltd. All rights reserved.
Table 1
Factors contributing to the clinical decision on appropriate antimicrobial therapy in
patients with suspected bacteremia
Characteristics of the patient
Age, underlying diseases, immunosuppression, malignancies, foreign bodies
International travel
Clinical specialty (e.g., surgery, ICU)1
Infection
Healthcare-acquired/community-acquired infection1
Infection type
Microbiology
Gram strain, deﬁnite microbial identiﬁcation
Molecular techniques
Infectious disease specialists consultation2
Antimicrobial resistance
Local situation
Global situation and trends
Clinical prediction rules4–6
Knowledge on Gram-stain + clinical categorization6
SIRS criteria 5
Clinical categorization criteria4
ICU, intensive care unit; SIRS, systemic inﬂammatory response syndrome.
Table 2
Schematic turnaround times of novel molecular methods in the detection of
bacteremia
Method Turnaround time
after positive
blood culture
Turnaround time
after whole
blood sample
Culture growth needed
Hybridization techniques 1.5–3 h 12–24+ (1.5–3 h)
Ampliﬁcation techniques 1–8 h 12–24+ (1–8 h)
Mass spectrometry methods 4–6 h 12–24+ (4 h)
Directly from blood sample
Whole blood ampliﬁcation methods - 6 h
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whenever intravenous antimicrobials are started. Rules aimed to
reduce blood culture orders might save money but may also result
in systematic failure to detect signiﬁcant bacteremia. The study by
Coburn and associates evokes discussion on what the role of novel
molecular methods would be in the diagnosis of bacteremia and
how the low sensitivity of blood cultures in detecting clinically
relevant bacteria could be overcome by other techniques. Clinical
prediction rules for estimating the probability of blood culture
positivity may be too complex for routine work.3–5
Effective empirical therapy is based on the accurate prediction
of the microbial etiology and the likelihood of a particular
infectious process. Gram stain results from positive blood cultures
often allow a rapid presumptive identiﬁcation of bacteria, and at
the same time may also provide early information as to the source
of bacteremia.6 Hautala and associates showed that second-
generation cephalosporins covered more than 70% of cocci in
clusters and over 80% of cocci in chains in community-acquired
infections, whereas in hospital-acquired infections the corre-
sponding ﬁgures were only 47% and 44%.6 Gram stains of positive
blood cultures are thus a rapid and cost-effective procedure, which
helps select the appropriate empirical antimicrobial therapy.
3. Microbiology in blood stream infections and the adequacy of
empirical therapy
European studies indicate that of all bacteria causing bacter-
emia, 44–48% are Gram-negative and 44–49% Gram-positive
organisms.1,7 The most common culprit is Escherichia coli and an
increasing role of Gram-negative bacteria has been documented
among blood isolates,1 especially as regards healthcare-associated
infections.8 The proportion of fungal bacteremia is clearly
dependent on whether the bacteremia is healthcare- or commu-
nity-acquired and on the clinical specialty in question,1 and there is
clear variation between prevalences in studies conducted in
different countries.1,7 An increase in Gram-negative organisms as a
cause of healthcare-acquired infections has been reported, and the
proportion of healthcare-acquired infections from the Candida
species almost doubled from 5.8% in 1999 to 11.3% in 2003.8 The
risk of candidemia is related to the degree of immunosuppression.9
Empirical antimicrobial treatment frequently fails.2,10,11 Bacte-
rial resistance further increases the risk of inadequate empirical
therapy.11,12 Recent studies conducted in Western European
countries have shown that more than 50% of patients with
methicillin-resistant Staphylococcus aureus (MRSA) bacteremiareceive inadequate empirical therapy for their condition.11,12 Thus,
early detection of bacterial resistance would be of particular
interest in clinical work. There are resistance mechanisms that
may be elucidated by molecular methods (e.g., mecA gene).
However, the resistance of pathogens that use several mechanisms
(e.g., Pseudomonas aeruginosa) cannot be determined without
conventional blood culture methods.
Providing rapid susceptibility results by conventional methods
can lead to timely changes to appropriate antimicrobial therapy
and the costs are lower than with novel methods.13,14 These
beneﬁts are best realized when coupled with extended laboratory
stafﬁng schedules and real-time transmission of susceptibility
results to clinicians.15 Rapid susceptibility tests may be applicable
in the detection of fast-growing bacteria, e.g. S. aureus and E. coli.
4. What are the beneﬁts and caveats of novel molecular
methods in detecting bacteremia?
An ideal technique would give a deﬁnite bacterial identiﬁcation
directly from a blood sample taken on patient admission or upon
suspicion of bacteremia. This is not at the moment possible
(Table 2).16 Both conventional blood culture techniques and most
novel techniques usually require blood culture growing bacteria
before identiﬁcation (Table 3). Novel molecular methods including
nucleic acid hybridization, ampliﬁcation, and mass spectrometry
have been developed to provide rapid identiﬁcation of organisms
recovered in blood cultures. Amongst the ampliﬁcation-based
methods, PCR is that most commonly used. The fastest microbio-
logical method at the moment is the multiplex real-time PCR
method Septifast (SF), which may yield a diagnosis within 6 h from
blood sampling.17 Most of the current methods require culture
growing bacteria before identiﬁcation, which means that the
critical hours in bacteremia and sepsis treatment are lost.
There is a lack of trial data to deﬁne the clinical reliability of
novel molecular methods in the diagnosis of bacteremia directly
from blood samples in patients who develop SIRS or sepsis.17 This
is due to a lack of standardized technology platforms meeting
accepted regulatory standards for clinical diagnosis. How to test
clinical reliability and what would be the gold standard method? In
studies evaluating, for example, the performance of novel
methods, blood cultures have been used as the reference method.17
Conclusions on clinical relevance may be difﬁcult to draw. The
probability of bacteremia in cohort studies is generally higher than
that of true-positive ﬁndings in a series of consecutive blood
cultures. This is due to patient selection; patients are selected for
studies on the basis of clinical signs and symptoms possibly
suggestive of bacteremia.3 Systematic protocols to evaluate the
clinical signiﬁcance of novel methods in light of accumulated
cohort studies have been planned.17 To better understand the
clinical beneﬁts of novel methods, an antimicrobial treatment
study guided by the use of these methods should be conducted.
The available data indicate that positive results obtained by a
more rapid novel method may reduce the inappropriate use of
Table 3
Advantages and shortcomings of novel molecular methods in the diagnosis of bacteremia
Advantages of novel methods Shortcomings/challenges of novel methods
Faster than conventional BCs Critical hours (1 to 2 h) after diagnosis of sepsis are still lost
May yield better sensitivity than BCs Pathogen panels may not include all potential culprit organisms
Decreased detection of blood culture contaminants? Susceptibility testing not available (e.g., the sensitivity of Pseudomonas aeruginosa
cannot be determined)
Better detection in antimicrobial- pretreated patients Detects DNAemia, not bacteremia. May detect dead organisms (ﬁnding does not
necessitate living bacteria)
May detect speciﬁc resistance proﬁles (e.g., mecA gene) Discordant results in studies with conventional BCs, lack of ideal
reference method makes it difﬁcult to evaluate the real clinical
impact of these methods
Clinical evaluation still needed, data indicate that more rapid microbiological
diagnosis does not ensure more rapid adequate antimicrobial therapy23
BC, blood culture.
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and hospitalization.18 Novel methods may help to detect bacteria
in antimicrobial-pretreated patients (Table 4).18–37 Even though
the sensitivity of the SF method has been found in many studies to
be comparable to that of conventional blood cultures, some studies
indicate that negative results in SF must be interpreted with
caution.18–20 There are data indicating that ampliﬁcation methods
may not detect all clinically relevant bacteremia and that the
pathogen panels do not include all clinically relevant bacteria.18,20
Analysis of concordance has evidenced a low correlation between
the two approaches, mainly considering samples testing negative
by culture but positive using the molecular approach.38 A
combination of conventional and novel molecular methods may
yield an enhanced rate of pathogen detection.18–21 Molecular
methods may also yield better sensitivity in the detection of
fungi.18 One recent study indicated that although implementation
of the PCR method signiﬁcantly reduced the time to bacterial
identiﬁcation, the time to optimal antibiotic therapy was not
signiﬁcantly reduced. Thus, to realize this potential beneﬁt,
processes must be optimized and additional interventions initiated
to facilitate providers’ use of the PCR result.22 In addition, there
may be difﬁculties in applying novel methods in the routine
microbiology laboratory.23
An intriguing opportunity with novel PCR-based methods is
the capacity to measure bacterial load.24 This could help to
evaluate treatment response in patients with sepsis. Chuang and
associates have studied sequential bacterial DNA loads in the
blood by a quantitative PCR assay in Acinetobacter bacteremia
and found the use of immunosuppressants to be an independent
predictor of slower bacterial clearance, while appropriate
antibiotic usage was an independent predictor of more rapid
bacterial clearance.24 Patients with a slower rate of bacterial
clearance experienced higher in-hospital mortality.24 One study
conducted among patients with suspected community-acquiredTable 4
Patient groups in which novel methods for the detection of blood stream infection hav
Would potentially beneﬁt in light
of cohort studies
The rationale 
Antimicrobial-pretreated patients Novel methods detect more bacteria in antimic
pretreated. Valuable additional tool.
Immunocompromised patients/
neutropenia patients
May lead to more rapid diagnosis and targeted
Improved detection of signiﬁcant bacteria. Valu
May yield better fungal detection.
SIRS/sepsis PCR detects potentially signiﬁcant bacteria and
BC. Additional tool. PCR resulted in earlier adju
therapy. Decreased detection of contaminants.
of fungi. Has the potential to become a cost-ef
managing sepsis.
Neonatal sepsis patients Useful additional tool. 
BC, blood culture; SIRS, systemic inﬂammatory response syndrome.bacteremia found that the test had high speciﬁcities and high
negative predictive values for the detectable pathogens. However,
the sensitivities and positive predictive values (PPVs) of the test
were suboptimal.25
Resistance mechanisms detected by molecular methods do not
necessarily correlate with phenotypic resistance, the gold standard
for reporting, nor are they known to predict treatment failure. The
over-reporting of potential resistance, in the absence of meaning-
ful data on correlation with resistant phenotype, is problematic
and has the potential to further escalate the inappropriate use of
broad-spectrum antibiotics. This is a signiﬁcant limitation to the
broad application of novel methods.
In the absence of antibiotic therapy, negative blood cultures
may help to exclude infection as a cause of fever. The negative
predictive value of a blood culture after 3 days of continuous
monitoring is good enough to allow discontinuation of antibiotics
for many patients. Thus, blood culture is a cost-effective method
that can reduce the use of antimicrobials.
5. Time is of the essence in sepsis
The focus on improving outcomes in sepsis has centered on
improvement in early hemodynamic resuscitation, development of
novel adjunctive therapies, and deployment of antimicrobials of
increasing potency. However, the current studies show conclu-
sively that early recognition of sepsis and rapid initiation of
appropriate antimicrobial therapy is the critical element in
improving survival.26 Broad-spectrum antimicrobials within 1 h
vs. no treatment within 6 h of diagnosis is associated with
decreased mortality in sepsis.20 Effective antimicrobial adminis-
tration within the ﬁrst hour of documented hypotension has been
shown to be associated with improved survival to hospital
discharge in septic shock.27 Inappropriate initial antimicrobial
therapy for septic shock occurs in about 20% of cases and ise been studied and would potentially beneﬁt from the use of these methods
Areas of uncertainty/caveats
robial- Cost-effects? Impact on infection outcome?
 antimicrobial use.
able additional tool.
Cost-effects? Impact on infection outcome?
 fungi not found by
stment of antimicrobial
 More rapid detection
fective component for
BC found pathogens not detected by PCR.
Some signiﬁcant organisms not in the PCR menu.
Insufﬁcient susceptibility of ampliﬁcation methods.
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empirical antimicrobial therapy frequently fails and the mortality
rate is high.10 However, one large cohort study conducted in the
USA and Canada indicated that only 50% of septic shock patients
received effective antimicrobial therapy within 6 h of documented
hypotension.27Mortality increased by 7.6% each hour of delay after
onset of hypotension.27 No studies have been published supporting
a sepsis survival beneﬁt from prompt microbiological diagnosis.
While novel molecular methods might reduce the time required
for bacterial identiﬁcation, they would not generate reliable
antimicrobial susceptibility data any faster than conventional
methods.
Source control is essential in several infectious diseases,
especially in gastrointestinal infections or staphylococcal abscess-
es. Rapid identiﬁcation of a microbe leads to a more rapid infection
diagnosis and may hasten surgical treatment and source control in
such patients. The use of broad-spectrum antimicrobials increases
antimicrobial resistance. The opportunity to speed up microbio-
logical diagnosis would cut down the period of use of broad-
spectrum antimicrobials in bacteremia.
6. Local microbiology and the requirement for novel methods
in the detection of antimicrobial resistance in bacteremia
Knowledge on local antimicrobial resistance is essential in
clinical work in order to select accurate empirical antimicrobial
therapy. Local differences in bacterial antimicrobial resistance
cause differences in the regional need of, for example, PCR methods
for the early detection of the resistance mechanism. For example in
Finland, there are substantial regional variations in the incidence of
MRSA bacteremia, as 9–15% of all S. aureus bacteremia is caused by
MRSA in the Pirkanmaa Health District, while the corresponding
ﬁgure in other parts of the country is between 1% and 2%.12 There is
a need for early detection of the culprit organism so that
antimicrobial therapy can be accurately targeted and subsequently
tapered off. The laboratory capacity and requirements for the
detection of resistance mechanisms should be tailored locally. The
detection of ESBL-producing strains by molecular methods is more
complex, as there is no single universal PCR method for the
detection of ESBL mechanisms, and the ESBL gene sought should be
known already before detection is undertaken. Because the arsenal
of novel methods in the diagnosis of bacteremia may not be clear to
all clinicians, the implementation of novel methods in clinical use
requires active discussion between laboratory experts and
clinicians.
7. Conclusions
Previous data indicate that novel molecular methods constitute
useful additional approaches besides conventional blood culture-
based methods in patients with suspected sepsis and may be
valuable especially in antimicrobial-pretreated cases. However,
there have been no randomized trials to evaluate the real clinical
and economic impact of these methods. The empirical antimicro-
bial selection in cases of sepsis is still based on clinical evaluation,
knowledge on local antimicrobial resistance, and on whether the
infection is healthcare- or community-acquired. The utilization of
Gram stain information in combination with clinical categorization
is still a rapid and valuable means of evaluating the adequacy of
empirical treatment and may also be used in resource-limited
areas.
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